Compare AMLX & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMLX | TSLX |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2021 | 2011 |
| Metric | AMLX | TSLX |
|---|---|---|
| Price | $17.61 | $19.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $20.11 | ★ $21.72 |
| AVG Volume (30 Days) | ★ 1.2M | 673.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.56% |
| EPS Growth | ★ 65.46 | N/A |
| EPS | N/A | ★ 1.81 |
| Revenue | ★ $380,786,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.20 |
| P/E Ratio | ★ N/A | $10.72 |
| Revenue Growth | ★ 1612.94 | N/A |
| 52 Week Low | $4.41 | $16.99 |
| 52 Week High | $18.61 | $25.17 |
| Indicator | AMLX | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 59.75 |
| Support Level | $13.19 | $17.25 |
| Resistance Level | N/A | $22.46 |
| Average True Range (ATR) | 0.91 | 0.49 |
| MACD | 0.26 | 0.19 |
| Stochastic Oscillator | 83.26 | 78.51 |
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.